I predicted this at the begininng...I thought it to be a fair price, and they EKA's asstes were very specfic and would proably not have attracted a trumping bid.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%